TORONTO, Feb. 28 /PRNewswire-FirstCall/ - Novadaq(R) Technologies Inc. , today announced a patent grant in Japan for its SPY(R) Intra-operative Imaging System. The Japanese Patent, 3881550, assigned to the National Research Council of Canada and exclusively licensed to Novadaq Technologies Inc. is titled "Method and Apparatus for Performing Intra-operative Angiography."
The SPY System enables cardiac surgeons to clearly visualize the flow of blood through grafts during bypass procedures. Protection for this core imaging technology in Japan represents a major commercial breakthrough for Novadaq. The Japanese patent reinforces Novadaq's global strategy to build a strong portfolio of protection for its innovative technology products and emerging pipeline and further strengthens Novadaq's position as the imaging company of the operating room.
"We at NRC are delighted to see our technology spreading around the world to ensure the functionality of cardiac bypasses," said Dr. Ian C.P. Smith, Director General, Institute for Biodiagnostics, National Research Council Canada. "Our partnership with Novadaq is a source of great pride to us".
About Novadaq Technologies
Novadaq Technologies Inc. develops and commercializes medical imaging devices for use in the operating room. Novadaq's proprietary imaging platform can be used to visualize blood vessels, nerves and the lymphatic system during surgical procedures. Novadaq's SPY Intra-operative Imaging System, commercially available worldwide, enables cardiac surgeons to visually assess coronary vasculature and bypass graft functionality during the course of open-heart surgery. Novadaq's OPTTX System which received CE Mark approval in November 2006, is aimed at the diagnosis, evaluation and treatment of wet Age-related Macular Degeneration (AMD) by using the same core imaging technology that is used in the SPY System. The HELIOS(TM) System, which received FDA clearance in January 2007, is the first fluorescent imaging system available for use during plastic reconstructive surgery allowing surgeons to evaluate pre- and intra-operative blood flow, as well as post-surgery perfusion. Novadaq's LUNA(TM) system is designed to enable surgeons to visualize nerve bundles during the course of urological and neurological procedures. LUNA has been granted a license for use by Health Canada. For more information, please visit the company's website at www.novadaq.com.
Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on Novadaq's current beliefs as well as assumptions made by and information currently available to Novadaq and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by Novadaq in its public securities filings; actual events may differ materially from current expectations. Novadaq disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Novadaq Technologies Inc.CONTACT: Arun Menawat, PhD, MBA, President & CEO, Novadaq TechnologiesInc., Phone: (905) 629-3822 x 202, amenawat@novadaq.com; Michael Moore, TheEquicom Group, (416) 815-0700 x 241, mmoore@equicomgroup.com